Nagy Monika, Schulz-Ertner Daniela, Bischof Marc, Welzel Thomas, Hof Holger, Debus Jürgen, Combs Stephanie E
Department of Radiation Oncology University Hospital of Heidelberg, Heidelberg, Germany.
Tumori. 2009 May-Jun;95(3):317-24. doi: 10.1177/030089160909500308.
Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas. In most analyses, WHO grade III and 1V tumors are not analyzed separately. The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients. Median age was 48 years. After the primary diagnosis, a biopsy had been performed in 72 patients; subtotal and total resections were performed in 37 and 18 patients, respectively. In all patients radiotherapy was applied with a median dose of 60 Gy in conventional fractionation. The median follow-up time was 18 months.
Median overall survival was 17 months. Overall survival was significantly influenced by the extent of surgery. Median overall survival was 32 months after complete resection, 36 months after subtotal resection, and 12 months after biopsy. Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas. Age significantly influenced overall survival. Median progression-free survival was 9 months; the extent of neurosurgical resection significantly influenced progression-free survival.
Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately. Radiochemotherapy might further improve outcome.
间变性胶质瘤患者的总生存期比胶质母细胞瘤患者更有利。在大多数分析中,世界卫生组织(WHO)III级和IV级肿瘤未分开分析。本分析报告了WHO III级胶质瘤患者术后放疗后的结果。
1988年1月至2007年1月期间,127例WHO III级肿瘤患者接受了放疗;组织学分类为纯星形细胞瘤104例,少突星形细胞瘤12例,纯少突胶质细胞瘤11例。中位年龄为48岁。初次诊断后,72例患者进行了活检;37例和18例患者分别进行了次全切除和全切除。所有患者均采用常规分割放疗,中位剂量为60 Gy。中位随访时间为18个月。
中位总生存期为17个月。总生存期受手术范围的显著影响。完全切除后的中位总生存期为32个月,次全切除后为36个月,活检后为12个月。间变性星形细胞瘤患者的中位总生存期为7个月,混合性肿瘤患者为44个月,纯少突胶质细胞瘤患者为47个月。年龄显著影响总生存期。中位无进展生存期为9个月;神经外科切除范围显著影响无进展生存期。
与胶质母细胞瘤患者相比,WHO III级间变性星形细胞瘤、少突胶质细胞瘤和少突星形细胞瘤患者术后放疗后的总生存期良好,因此应分开分析。放化疗可能会进一步改善预后。